GemVax Appoints Lee Seok-jun, US Attorney, as President of Bio Division

GemVax & Kael announced on the 3rd that it has appointed attorney Seokjun Lee from the global law firm Latham & Watkins as the President of its Bio Business Division.

President Lee is a lawyer who graduated from Seoul National University with a degree in Economics and from Vanderbilt University Law School. He is an expert who has provided legal counsel across global corporate management for over 20 years.

He worked at the First Research Department and the Governor’s Secretariat of the Bank of Korea during the Korean foreign exchange crisis, and later served in the Corporate Finance Division of the U.S. Securities and Exchange Commission (U.S. SECURITIES AND EXCHANGE COMMISSION) when the Sarbanes-Oxley Act was enacted. He has experienced the capital market upheavals in both Korea and the United States.

Starting in 2005 at the U.S. Wall Street law firm Davis Polk & Wardwell, he provided legal counsel on overall corporate management at Clifford Chance and Latham & Watkins. He successfully led the listings of prominent domestic and international companies on the U.S., Hong Kong, and Korean stock exchanges.

With President Lee’s rich experience and understanding of domestic and international companies, GemVax plans to concretize the commercialization strategy of GV1001, which is being developed as a treatment for neurodegenerative diseases such as Alzheimer’s disease and progressive supranuclear palsy (hereinafter PSP), and actively pursue domestic and foreign investment attraction.

President Lee said, "GemVax has continuously conducted research and development in the field of neurodegenerative diseases and has proven the efficacy of GV1001 as a treatment. As I take on a key role at this important time when we must prepare for fruition, I will devote all my capabilities to ensure smooth development, commercialization, and active investment attraction."

GemVax is currently developing a new drug, having recently submitted a Phase 2 clinical trial application (IND) for the PSP treatment GV1001 to the U.S. Food and Drug Administration (FDA).